OGN

NYSE · Pharmaceuticals

Organon & Co

Small-Cap Stocks Stocks Under $10 Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$6.03

-0.24 (-3.83%)

As of Mar 22, 10:03 PM ET ·

Financial Highlights (FY 2026)

Revenue

6.19B

Net Income

186.08M

Gross Margin

53.3%

Profit Margin

3.0%

Rev Growth

+0.2%

D/E Ratio

11.49

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	6.19B	6.17B	515.23M	479.67M
Gross Profit	3.30B	3.29B	145.97M	135.89M
Operating Income	423.09M	379.91M	143.74M	141.87M
Net Income	186.08M	167.09M	144.40M	138.60M
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%
Rev Growth	+0.2%	+0.2%	+11.5%	-9.2%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	750.77M	750.77M	937.97M	935.09M
Total Equity	65.31M	65.31M	1.31B	1.37B
D/E Ratio	11.49	11.49	0.71	0.68

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	1.09B	1.04B	186.20M	184.13M
Free Cash Flow	—	—	113.95M	97.08M